ESMO 2023 special: Dr. Van Der Heijden talks about the phase 3 CheckMate 901 trial results
EAU Podcasts - Un podcast de European Association of Urology - Les dimanches
Catégories:
In this podcast from ESMO 2023, UROONCO BCa associate editor Dr. Laura Mertens (NL) talks with Dr. Michiel Van Der Heijden (NL) on his abstract “Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial”. Dr. Van Der Heijden shares details on the design of the trial and the late-breaking results that he presented at ESMO 2023. Primary endpoints were met with ove...
